Table 2 Results; cohort studies
Study | Subjects (age , male) | Median follow-up time (yrs) | Outcome | Results |
|---|---|---|---|---|
Katzmarzyk [19] | N = 19,173 | 10 | All-cause mortality CVD mortality | MHO = All cause: 25 (3%); CVD: 12 (1%); MHNW = All-cause: 160 (2%); CVD: 38 (1%); |
MHO = 1,019 (43, 100%) | •Unadjusted HR for MHO vs. MHNW = NR (All-cause); NR (CVD) | |||
MHNW = 7,153 (41, 100%) | •AdjustedA HR for MHO vs. MHNW = 0.88 (0.57-1.36) [All-cause]; 1.59 (0.81-3.12) [CVD] | |||
St-Pierre [17] | N = 1,824 | 13 | Incident CVD | Total = 284 (16%); MHO = NR; MHNW = NR |
MHO = 54 (NR, 100%) | •Unadjusted HR for MHO vs. MHNW = NR | |||
MHNW = 512 (NR, 100%) | •AdjustedB HR for MHO vs. MHNW = 1.53 (0.79-3.00) | |||
Meigs [14] | N = 2,902 | 11 | Incident CVD | MHO = CVD: 19 (8%); MHNW = CVD: 19 (5%); |
MHO = 236 (52, 51%) | •Unadjusted RR for MHO vs. MHNW = NR | |||
MHNW = 981 (52, 27%) | • AdjustedC RR for MHO (MetS) vs. MHNW = 1.48 (0.87-2.55)[CVD] | |||
•AdjustedC RR for MHO (IS) vs. MHNW = 1.42 (0.87-2.33) [CVD] | ||||
Daly [20] | N = 8,397 (60, 87%) | 4 | CVD mortality | MHO = NR (3%); MHNW = NR (2%) |
MHO = 839 (NR,NR) | •Unadjusted RR for MHO vs. MHNW = 1.42 (0.76-2.63) | |||
MHNW = NR | •Adjusted RR for MHO vs. MHNW = NR | |||
Song [21] | N = 25,626 | 10 | Incident CVD | MHO = CVD: 77 (3%); MHNW = CVD: 278 (2%) |
MHO = 2,925 (54, 0%) | •Unadjusted RR for MHO vs. MHNW = NR | |||
MHNW = 12,943 (54, 0%) | •AdjustedD RR for MHO vs. MHNW = 1.05 (0.66-1.66) | |||
•AdjustedE RR for MHO vs. MHNW = 1.07 (0.68-1.70) | ||||
Kuk [13] | N = 6,011 | 9 | All-cause mortality | Total = 292 (5%); MHO = NR; MHNW = NR |
MHO = 78 (NR, NR) | •Unadjusted RR for MHO (MetS) vs. MHNW = NR | |||
MHNW = 1,461 (NR, NR) | •AdjustedF RR for MHO (MetS) vs. MHNW = 2.80 (1.18-6.65) | |||
•Unadjusted RR for MHO (IS) vs. MHNW = NR | ||||
•AdjustedF RR for MHO (IS) vs. MHNW = 2.58 (1.00-6.65) | ||||
Arnlov [9] | N = 1,758 | 30 | All-cause mortality | MHO = All-cause: 18 (60%); CVD mortality: 5 (17%) MHNW = All-cause: 391 (44%); CVD mortality: 155 (17%) |
MHO = 30 (50, 100%) | CVD mortality | •Unadjusted RR for MHO (MetS) vs. MHNW = NR | ||
MHNW = 891 (50, 100%) | Incident CVD | • AdjustedG RR for MHO (MetS) vs. MHNW = 1.65 (1.03-2.66) [All-cause]; 1.20 (0.49-2.93) [CVD mortality]; 1.95 (1.14-3.34) [Incident CVD] | ||
• AdjustedG RR for MHO (IS) vs. MHNW = 2.04 (1.25-3.32) [All-cause]; 1.80 (0.79-4.08) [CVD mortality]; 1.91 (1.07-3.41) [Incident CVD] | ||||
Calori [10] | N = 2,011 | 15 | All-cause mortality | MHO = All-cause: 7 (16%); CVD: 2 (5%) MHNW = All-cause: 141 (20%); CVD: 58 (8%) |
MHO = 43 (55, 28%) | CVD mortality | •Unadjusted HR for MHO vs. MHNW = NR | ||
MHNW = 708 (55, 45%) | •AdjustedH HR for MHO vs. MHNW = 0.99 (0.46-2.11) [All-cause]; 0.73 (0.18-3.00) [CVD] | |||
Voulgari [18] | N = 550 (60, NR) | Incident heart failure | MHO = 43 (9%); MHNW = 17 (16%) | |
MHO = 96 (NR, NR) | 6 | •Unadjusted HR for MHO vs. MHNW = 0.26 (NR) | ||
MHNW = 109 (NR, NR) | •AdjustedI HR for MHO vs. MHNW = 0.41 (0.10-1.31) | |||
Hosseinpanah [12] | N = 6,215 | 8 | Incident CVD | MHO = 13 (3%); MHNW = 64 (4%) |
MHO = 408 (45, 20%) | •Unadjusted HR for MHO vs. MHNW = NR | |||
MHNW = 1,555 (45, 57%) | •AdjustedJ HR for MHO vs. MHNW = 1.07 (0.59-1.96) | |||
Bobbioni Harsch [23] | N = 436 | 3 | CCA-IMT | Male Subjects Mean CCA-IMT at Baseline: MHO = 0.63 (0.07) vs. MHNW = 0.59 (0.08) p = NS |
MHO = 65 (45, 42%) | Mean CCA-IMT at 3 years: MHO = 0.62 (0.10) vs. MHNW = 0.60 (0.07) p = NS | |||
MHNW = 194 (43, 23%) | Female Subjects Mean CCA-IMT at Baseline: MHO = 0.57 (0.06) vs. MHNW = 0.56 (0.06) p = NS | |||
Mean CCA-IMT at 3 years: MHO = 0.61 (0.08) vs. MHNW = 0.58 (0.06) p < 0.05 | ||||
Ogorodnikova [15] | N = 17,544 | 12 | Incident CVD | Total = 2,439 (14%); MHO = NR; MHNW = NR |
MHO = 1,167 (56, 32%) | •Unadjusted HR for MHO vs. MHNW = NR | |||
MHNW = 4,036 (58, 33%) | •AdjustedK HR for MHO (using various definitions) vs. MHNW = 1.30 (1.03-1.66) [ATP III definition]; 1.17 (0.87-1.57) [ATP-III Expanded]; 1.52 (1.19-1.95) [IS definition] | |||
Hamer [11] | N = 22,203 | 7 | All-cause mortality | MHO = All-cause: 38 (3%); CVD: 18 (2%); |
MHO = 1,160 (51.3, 53%) | CVD mortality | MHNW = All-cause: 777 (6%); CVD: 225 (2%) | ||
MHNW = 12,716 (51.9, 45%) | •Unadjusted HR for MHO vs. MHNW = NR | |||
•AdjustedL HR for MHO v. MHNW = 0.91 (0.64-1.29) [All-cause]; 1.26 (0.74-2.13) [CVD] | ||||
Bo [22] | N = 1,658 | 9 | All-cause mortality | MHO = All-cause: 15 (21%); CVD mortality: 8 (11%); Incident CVD: NR (8%) |
MHO = 72 (55, 33%) | CVD mortality | MHNW = All-cause: 28 (5%); CVD mortality:7 (1%);Incident CVD: NR (3%) | ||
MHNW = 540 (54, 38%) | Incident CVD | •Unadjusted HR for MHO vs. MHNW = NR | ||
•AdjustedM HR for MHO vs. MHNW = 1.36 (0.64-2.08) [All-cause]; 2.48(1.35-3.61) [CVD mortality]; 2.76 (1.05-7.28) [Incident CVD] | ||||
Ortega [16] | N = 43,265 | 14 | All-cause mortality | MHO = All-cause: 52 (3%); CVD mortality: 17 (1%); Incident CVD: 30 (6%) |
MHO = 1,738 (NR, 80%) | CVD mortality | MHNW = All-cause: 449 (3%); CVD mortality: 98 (1%); Incident CVD: 261 (4%) | ||
MHNW = 16,002 (NR,NR) | Incident CVD | •Unadjusted HR for MHO(referent) vs. MHNW = NR | ||
•AdjustedN HR for MHO(referent) vs. MHNW = 0.91(0.67-1.24) [All-cause]; 0.73 (0.42-1.28) [ CVD mortality]; 0.78 (0.52-1.18) [Incident CVD] |